M&A

Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc.

February 14, 2018

SOUTH SAN FRANCISCO, Calif. & ATLANTA–(BUSINESS WIRE)–Vaxart, Inc. (NASDAQ: VXRT) today announced the completion of its merger with Aviragen Therapeutics, Inc. In connection with the merger, Aviragen Therapeutics, Inc. changed its name to Vaxart, Inc. and effected a 1-for-11 reverse split of its common stock. The combined company will commence trading on a post-reverse split […]

Astellas Acquires Universal Cells, Inc.

February 14, 2018

TOKYO, Feb. 13, 2018 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today announced that Astellas has acquired Universal Cells. Astellas will gain Universal Cells’ proprietary Universal Donor Cell technology to create cell therapy products that do not require Human Leukocyte […]

Avadel Pharmaceuticals Announces Divestiture of Pediatric Business

February 13, 2018

DUBLIN, Ireland, Feb. 12, 2018 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (NASDAQ:AVDL) (“Avadel” or “the Company”) today announced that it has entered into an asset purchase agreement with Cerecor, Inc (“Cerecor”) whereby Cerecor will acquire the Avadel pediatric portfolio. In connection with this transaction, Avadel and Cerecor will enter into a license and development agreement […]

Charles River Laboratories to Acquire MPI Research

February 13, 2018

WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire MPI Research for approximately $800 million in cash, subject to customary closing adjustments.   MPI is a premier non-clinical contract research organization (CRO) providing comprehensive testing services to biopharmaceutical and medical device companies worldwide. […]

Vaxart Provides Merger Update

February 12, 2018

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today it has reached an understanding with the CAS Group under which East Hill, a major shareholder in Aviragen, will support the merger between Vaxart and Aviragen.   “We want to […]

Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc.

February 9, 2018

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc. (NASDAQ:CASC) at a price of $10.00 per share net to the seller in cash, without interest, less any applicable withholding taxes […]

Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.

February 8, 2018

Paris – February 8, 2018 – Sanofi announced today that on February 7, 2018 it commenced a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of Bioverativ, Inc. (“Bioverativ”) for $105 per share in cash (the “Offer Price”), without interest thereon and net of any required tax withholding.   […]

Certara Acquires BaseCase, a Life Sciences Data Visualization Company

February 8, 2018

PRINCETON, N.J.–(BUSINESS WIRE)–Certara®, the global leader in model-informed drug development and regulatory science, today announced that it has acquired BaseCase Management GmbH, a data visualization software as a service (SaaS) company headquartered in Berlin, Germany, with offices in New York. BaseCase, which will join Certara’s Strategic Consulting Services division, has extensive Health Economics and Outcomes […]

J&J takes option on Theravance’s JAK drug in $1bn deal

February 8, 2018

Johnson & Johnson is paying $100m upfront for opt-in rights to a JAK inhibitor developed by Theravance, with another $900m in milestones on offer if development goes to plan.   It is the latest big pharma company to make a play in the market for JAK inhibitors used for immunological diseases, which is heating up […]

Celgene Corporation Commences Tender Offer for Juno Therapeutics, Inc.

February 5, 2018

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced that its wholly-owned subsidiary, Blue Magpie Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Juno Therapeutics, Inc. (NASDAQ: JUNO) at a price of $87.00 per share, net to the seller in cash, without interest and less required withholding taxes. The […]

Certara Acquires BaseCase, a Life Sciences Data Visualization Company

February 2, 2018

PRINCETON, N.J.–(BUSINESS WIRE)–Certara®, the global leader in model-informed drug development and regulatory science, today announced that it has acquired BaseCase Management GmbH, a data visualization software as a service (SaaS) company headquartered in Berlin, Germany, with offices in New York. BaseCase, which will join Certara’s Strategic Consulting Services division, has extensive Health Economics and Outcomes […]

Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.

February 2, 2018

Basel, February 1, 2018 – Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all of the outstanding ordinary shares (“Ordinary Shares”), including Ordinary Shares represented by American Depositary Shares (“ADSs”), of Advanced Accelerator Applications S.A. (NASDAQ: AAAP) […]

Aviragen Provides New Information Supporting Vote FOR Vaxart Merger

February 1, 2018

ATLANTA, Jan. 31, 2018 (GLOBE NEWSWIRE) — Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today issued the following statement urging stockholders to vote FOR the Company’s proposed merger with Vaxart, Inc. on the WHITE proxy card. The voting period will close at the upcoming Special Meeting of Stockholders on February 6, 2018. Aviragen’s Board of Directors and management […]

Harvard Bioscience Completes Acquisition of Data Sciences International

February 1, 2018

HOLLISTON, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq:HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, announced today that the Company has completed the previously announced acquisition of Data Sciences International, Inc. (“DSI”). The aggregate consideration payable by the Company in […]

Partner Therapeutics (PTx) Acquires Leukine® from Sanofi

February 1, 2018

BOSTON, Feb. 1, 2018 /PRNewswire/ — Boston-based cancer company Partner Therapeutics, Inc. (PTx) announced today that it has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi. Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body’s immune […]

Vaxart Issues Statement Regarding Proposed Merger With Aviragen

February 1, 2018

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. today commented on the Company’s proposed merger with Aviragen Therapeutics, Inc. (NASDAQ:AVIR). The following is a statement from Wouter Latour, M.D., Chief Executive Officer of Vaxart, who will lead the combined company following completion of the transaction:   We are thrilled with the prospects of combining forces with Aviragen. […]

Teva Announces Completion of Global Women’s Health Divestiture to CVC Capital Partners

February 1, 2018

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced it has completed the sale of a portfolio of products within its global women’s health business across contraception, fertility, menopause and osteoporosis for $703 million in cash. The portfolio, which is marketed and sold outside of the U.S., includes Ovaleap®, Zoely®, Seasonique®, Colpotrophine®, Actonel® […]

Certara Acquires BaseCase, a Life Sciences Data Visualization Company

February 1, 2018

Acquisition will add strong visualization and communications capabilities across Certara’s data science decision-support value chain Certara®, the global leader in model-informed drug development and regulatory science, today announced that it has acquired BaseCase Management GmbH, a data visualization software as a service (SaaS) company headquartered in Berlin, Germany, with offices in New York. BaseCase, which […]

Sanofi to Acquire Ablynx for €3.9 Billion

January 29, 2018

PARIS, France and GHENT, Belgium, 29 January 2018 – Sanofi [Euronext: SAN; NYSE: SNY] and Ablynx [Euronext Brussels and Nasdaq: ABLX], a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American […]

CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)

January 29, 2018

ROCKVILLE, Md., Jan. 26, 2018 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing quality pharmaceutical products to the Chinese and U.S. markets announced today that it has acquired a portfolio of 25 U.S. FDA-approved abbreviated new drug applications (ANDAs), one ANDA that FDA tentatively approved, and three ANDAs that are […]

Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment of Neurological and Neurodegenerative Conditions

January 25, 2018

NEWTON, Mass. – January 25, 2018 –Karyopharm Therapeutics Inc. (NASDAQ:KPTI) today announced its entry into an agreement for Biogen to acquire Karyopharm’s investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions. KPT-350 is a novel therapeutic candidate that works by inhibiting XPO1, resulting in reductions in inflammation […]

Celgene to Buy Juno Therapeutics for $9 Billion Deal, priced at $87 a share, adds to the biotech’s arsenal of blood-cancer drugs

January 25, 2018

Celgene Corp. CELG -1.38% on Monday said it agreed to buy Juno Therapeutics Inc. JUNO -0.08% for $87 a share in cash, or about $9 billion, in a move that will expand Celgene’s portfolio of blood-cancer drugs.   The Wall Street Journal reported last week the two companies were in deal talks.   The deal […]

Biotech’s $20 Billion Merger Monday Sparks Hope for More Deals

January 25, 2018

Three weeks into 2018, deal activity in the biotech sector is already almost halfway to what it was in 2017, at least in terms of size.   In the early hours of Monday morning, French drug giant Sanofi said it would buy hemophilia drugmaker Bioverativ, a Biogen spinout that is less than a year old, […]

Astellas Completes Acquisition of Mitobridge, Inc.

January 24, 2018

TOKYO, Jan. 23, 2018 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Mitobridge, Inc. (“Mitobridge”), and Mitobridge has become a wholly owned subsidiary of Astellas as of January 23, 2018 (U.S. Eastern Time).   By exercising the option right to […]

Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer

January 23, 2018

SAINT-GENIS-POUILLY, France, Jan. 22, 2018 (GLOBE NEWSWIRE) — Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), a leader in nuclear medicine theragnostics, today announced that a subsidiary of Novartis AG (NYSE:NVS) (“Novartis”), Novartis Groupe France S.A. (“Purchaser”), has successfully completed a tender offer to purchase all of the outstanding ordinary shares (“Ordinary Shares”), including […]

BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases

January 23, 2018

RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., Jan. 22, 2018 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), today announced that they have signed a definitive merger agreement to form a new enterprise focused on the development and commercialization of medicines to serve more patients suffering from rare diseases. The combined […]

Avista Pharma Solutions Acquires Solid Form Solutions

January 23, 2018

DURHAM, N.C.–(BUSINESS WIRE)–Avista Pharma Solutions, Inc. (“Avista Pharma”) announced today that it has completed the acquisition of Solid Form Solutions, Ltd. located in Edinburgh, Scotland. Solid Form Solutions is a leading provider of solid state chemistry and crystallization development services for clients in the pharmaceutical industry. The addition of Solid Form Solutions further expands Avista […]

Sanofi to Acquire Bioverativ for $11.6 Billion

January 22, 2018

Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases Adds leader in the growing hemophilia market and provides platform for expansion in other rare blood disorders Drives meaningful shareholder value with ROIC expected to exceed cost of capital within three years Enhances Sanofi’s sustainable revenue and earnings growth Provides immediate Business EPS […]

Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period

January 22, 2018

Basel, January 22, 2018 – Novartis AG (NYSE: NVS) today announced the successful completion of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all of the outstanding ordinary shares (“Ordinary Shares”), including Ordinary Shares represented by American Depositary Shares (“ADSs”), of Advanced Accelerator Applications S.A. (NASDAQ: AAAP) (“AAA”), for a price […]

Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy

January 22, 2018

SUMMIT, N.J. & SEATTLE–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno. Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash and […]

FEEDBACK